Lower back TET2.

This case report describes an important discovery in a patient who went into complete remission after being treated with CAR T-cell therapy for CLL. At the time of remission, >90% of all the patient’s CAR T-cells were expanded from a single clone. That’s right, a single clone. In this one clone, the CAR gene was inserted into the TET2 gene disrupting its activity, in addition to a different mutation in the other TET2 allele. In vivo, TET2 knockdown resulted in rapid T-cell expansion and potent anti-tumor effects, making this an attractive target in future efforts to enhance immunotherapy tumor kill. | Fraietta, Nature 2018